Health News Flash (Feb 28, 2021) - Nasopharyngeal cancer is prevalent in East and Southeast Asia. Despite the promising efficacy of immunotherapy in this tumor, there are no reliable biomarkers to select responsive candidates for immunotherapy. A recent study published in Mol Cancer entitled “Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses” reported the novel immune subtypes in nasopharyngeal cancer. The principal investigators virtually dissected the gene expression profiles and classified patients into the evaded, active, and non-immune subtypes, and further uncovered that patients with active immune subtype could largely benefit from anti-PD-1 therapy. Inspiringly, this is the first investigation that identifies predictors for immunotherapy in nasopharyngeal cancer. Future studies are warrant to investigate the applicability of this classification in clinical practice.
 
To know more information,
Visit: https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01292-5